Patents Assigned to ChemoCentryx, Inc.
  • Heteroaryl sulfonamides and CCR2
    Patent number: 7622583
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: November 24, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright
  • ARYL SULFONAMIDES
    Publication number: 20090270616
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 7, 2009
    Publication date: October 29, 2009
    Applicant: CHEMOCENTRYX, INC
    Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20090252779
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 8, 2009
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • Substituted piperazines
    Patent number: 7589199
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: September 15, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Andrew M. K. Pennell, James B. Aggen, J. J. Kim Wright, Subhabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi, Wei Chen, Penglie Zhang
  • Aryl sulfonamides
    Patent number: 7582661
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: September 1, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ugashe, Zheng Wei, John J. Wright, Andrew Pennell
  • 4-phenylpiperdine-pyrazole CCR1 antagonists
    Patent number: 7576218
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 18, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, Wei Chen, Kevin Lloyd Greenman, Lianfa Li, Edward J. Sullivan, Valeri V. Martichonok
  • Piperidine derivatives and methods of use
    Patent number: 7576106
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 18, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, Wei Chen, Kevin Lloyd Greenman, Edward J. Sullivan, Lianfa Li
  • Enzymatic activities in chemokine-mediated inflammation
    Patent number: 7572600
    Abstract: Truncated chemokines lacking an N-terminal region that activate CCR1 and/or FPRL1 and compositions containing the truncated chemokines are provided. Methods of identifying agents that modulate CCR1 and/or FPRL1 activity either by modulating the production of the truncated chemokines or the ability of the truncated chemokines to activate CCR1 and/or FPRL1 are also disclosed. Methods using the truncated chemokines to inhibit or activate CCR1 and/or FPRL1 mediated biological activities are also disclosed.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: August 11, 2009
    Assignee: Chemocentryx, Inc.
    Inventors: Robert D. Berahovich, Zhenhua Miao, Brett Premack, Thomas J. Schall
  • Substituted quinolones and methods of use
    Patent number: 7557213
    Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: July 7, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Anita Melikian, John Jessen Wright, Antoni Krasinski, Cheng Hu, Aaron Novack
  • Aryl Sulfonamides
    Publication number: 20090163498
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: June 11, 2008
    Publication date: June 25, 2009
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
  • Aryl Sulfonamides
    Publication number: 20090118307
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: October 15, 2008
    Publication date: May 7, 2009
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
  • Azaindazole compounds and methods of use
    Patent number: 7524845
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: April 28, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
    Publication number: 20090054630
    Abstract: Antibodies that bind CCX-CKR2 are described.
    Type: Application
    Filed: June 19, 2007
    Publication date: February 26, 2009
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • ANTIBODIES THAT BIND CXCR7 EPITOPES
    Publication number: 20090022717
    Abstract: Antibodies that bind CXCR7 epitopes, as well as methods of identifying CXCR7 modulators are described.
    Type: Application
    Filed: October 10, 2007
    Publication date: January 22, 2009
    Applicant: ChemoCentryx, Inc.
    Inventors: Brett Premack, Zhenhua Miao, Mark Penfold
  • N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL) HETARYL ARYLSULFONAMIDES
    Publication number: 20090005410
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: June 17, 2008
    Publication date: January 1, 2009
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • Method for multiple chemokine receptor screening for antagonists using RAM assay
    Patent number: 7468253
    Abstract: The present invention is directed to a modified cell migration assay allowing for improved identification and discrimination of chemokine receptor antagonists from non-specific migration blockers.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: December 23, 2008
    Assignee: Chemocentryx, Inc.
    Inventor: Zheng Wei
  • 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES
    Publication number: 20080300257
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: May 21, 2008
    Publication date: December 4, 2008
    Applicant: ChemoCentryx, Inc.
    Inventors: Lianfa Li, Andrew M.K. Pennell, Penglie Zhang
  • ARYL SULFONAMIDES
    Publication number: 20080293717
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 2, 2008
    Publication date: November 27, 2008
    Applicant: CHEMOCENTRYX, INC.
    Inventors: SOLOMON UGASHE, Zheng Wei, J.J. Wright, Andrew Pennell
  • Substituted piperazines
    Patent number: 7449576
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: November 11, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subrabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi
  • OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS
    Publication number: 20080269280
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: March 14, 2008
    Publication date: October 30, 2008
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, Lianfa Li, Edward J. Sullivan